| Lenihan And Hoffer Dental Psc | |
|
800 Violet Rd Ste 1 Crittenden KY 41030-8948 | |
| (859) 428-3100 | |
| (859) 428-3999 |
| Full Name | Lenihan And Hoffer Dental Psc |
|---|---|
| Speciality | Clinic/center - Dental |
| Location | 800 Violet Rd Ste 1, Crittenden, Kentucky |
| Authorized Official Name and Position | John Francis Lenihan (DENTIST) |
| Authorized Official Contact | 8594283100 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Lenihan And Hoffer Dental Psc 800 Violet Rd Ste 1 Crittenden KY 41030-8948 Ph: (859) 428-3100 | Lenihan And Hoffer Dental Psc 800 Violet Rd Ste 1 Crittenden KY 41030-8948 Ph: (859) 428-3100 |
| NPI Number | 1932792132 |
|---|---|
| Provider Enumeration Date | 02/18/2021 |
| Last Update Date | 09/01/2021 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932792132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QD0000X | Clinic/center - Dental | (* (Not Available)) | Primary |
| 332B00000X | Durable Medical Equipment & Medical Supplies | (* (Not Available)) | Secondary |
News Archive
A new brain imaging study of recently diagnosed schizophrenia patients has found, for the first time, that the loss of gray matter typically experienced by patients can be prevented by one of the new atypical antipsychotic drugs, olanzapine, but not by haloperidol, an older, conventional drug.
Do the same laws of biodiversity which apply in nature also apply to our own bodies and homes? If so, current hygiene measures to combat aggressive germs could be, to some extent, counterproductive.
Products from the Massachusetts pharmacy linked to the deadly meningitis outbreak passed a lab test in May, reports The Wall Street Journal. In addition, the pharmacy dodged a reprimand by Massachusetts regulators in 2004 after protesting it would be "fatal to the business." The company's founders come under scrutiny by media outlets as more people file lawsuits.
In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam achieved positive clinical results in a Phase I pharmacokinetic study.
› Verified 6 days ago